Ablation..........................................................................................120 |
ABO................................................................................................135 |
Active surveillance..........................................................................107 |
Anesthesia..........................................................................................1 |
Angiogenesis....................................................................................18 |
Autologous stem-cell transplantation..............................................143 |
BCG................................................................................................124 |
Benign prostatic hyperplasia...........................................................113 |
Benign renal tumor........................................................................158 |
Biopsy.................................................................................................1 |
Bladder.......................................................................6,18,89,124,127 |
Bladder neoplasms...........................................................................18 |
Bladder tumor..................................................................................51 |
Blood group...................................................................................135 |
Cancer-specific survival.....................................................................99 |
Cardiovascular disease risk................................................................59 |
Checkpoint blockers.........................................................................67 |
Complications..................................................................................46 |
Cost-benefit....................................................................................117 |
Cryotherapy....................................................................................120 |
Cystectomy......................................................................................89 |
Defensive surgery.............................................................................51 |
Detrusor muscle................................................................................51 |
Diagnostic marker............................................................................30 |
Early bladder chemotherapy instillation............................................24 |
Efficacy...........................................................................................143 |
Exenteration.....................................................................................89 |
Female..............................................................................................89 |
FNCLCC grading system...................................................................93 |
Framingham risk score......................................................................59 |
Genitourinary sarcomas....................................................................93 |
Germ cell tumors............................................................................143 |
Hepatititis.......................................................................................124 |
High-dose chemotherapy...............................................................143 |
Immunotherapy................................................................................67 |
Intravesical BCG...............................................................................24 |
Intravesical chemotherapy................................................................24 |
Invasion..............................................................................................6 |
lamina propria....................................................................................6 |
Laparoscopic surgery......................................................................154 |
Laparoscopy...................................................................................158 |
Lower urinary tract symptoms........................................................107 |
Lymphocyte-to-monocyte ratio......................................................138 |
Medical students..............................................................................10 |
MicroRNA-21....................................................................................30 |
Molecular markers.....................................................................18,127 |
MRI..................................................................................................55 |
mRNA expression...........................................................................149 |
Multilocular cystic renal cell carcinoma.............................................55 |
Nanomedicine..................................................................................34 |
Nanotechnology...............................................................................34 |
Nephrectomy..............................................................................59,99 |
Neutrophil-lymphocyte ratio............................................................40 |
Neutrophil-to-lymphocyte ratio......................................................138 |
Neutrophilto-monocyte ratio..........................................................138 |
Non-muscle invasive bladder tumor........................................24,30,40 |
Oncologic outcomes.........................................................................59 |
Outcomes.........................................................................................14 |
Overall survival.................................................................................93 |
Pain....................................................................................................1 |
Paratesticular sarcomas.....................................................................93 |
Partial nephrectomy................................................................154,158 |
Platelet-to-lymphocyte ratio............................................................138 |
Prognosis.....................................................................................18,99 |
Progression.......................................................................................40 |
Prostate..............................................................................................1 |
Prostate biopsy..........................................................................46,138 |
Prostate cancer..................................................14,34,67,107,113,138 |
PSMA...............................................................................................34 |
Radical nephrectomy......................................................................158 |
Radiofrequency ablation.................................................................120 |
Radiology.........................................................................................80 |
Radionuclide imaging.......................................................................80 |
RCC................................................................................................149 |
Recurrence, prognosis......................................................................40 |
Renal cell carcinoma..........................................................55,59,73,99 |
Renal leiomyoma............................................................................158 |
Renal tumor....................................................................................154 |
Resistance mechanisms.....................................................................73 |
Rhesus............................................................................................135 |
Risk factors.......................................................................................46 |
Robotic surgery.......................................................................117,154 |
Robotic-assisted laparoscopic prostatectomy....................................14 |
Small renal mass.............................................................................120 |
Smear ..............................................................................................89 |
Superficial...........................................................................................6 |
Survival.............................................................................................67 |
Survival analysis................................................................................99 |
Tamsulosin......................................................................................107 |
Testicular cancer........................................................................10,135 |
Testicular self-examination................................................................10 |
Theranostic concepts........................................................................34 |
TLR.................................................................................................149 |
Tumor markers.................................................................................18 |
TUR-BT.............................................................................................51 |
Tyrosine kinase inhibitors .................................................................73 |
Urinary biomarkers.........................................................................127 |
Urological neoplasms........................................................................80 |
Urology..........................................................................................117 |
Vaccine.............................................................................................67 |
Vitamin D.......................................................................................113 |